Publication delay of randomized trials on 2009 influenza A (H1N1) vaccination.

Randomized evidence for vaccine immunogenicity and safety is urgently needed in the setting of pandemics with new emerging infectious agents. We carried out an observational survey to evaluate how many randomized controlled trials testing 2009 H1N1 vaccines were published among those registered, and...

Full description

Bibliographic Details
Main Authors: John P A Ioannidis, Lamberto Manzoli, Corrado De Vito, Maddalena D'Addario, Paolo Villari
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2011-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC3229554?pdf=render
id doaj-980f7355ae4d47eab639f8003bd06582
record_format Article
spelling doaj-980f7355ae4d47eab639f8003bd065822020-11-25T00:44:18ZengPublic Library of Science (PLoS)PLoS ONE1932-62032011-01-01612e2834610.1371/journal.pone.0028346Publication delay of randomized trials on 2009 influenza A (H1N1) vaccination.John P A IoannidisLamberto ManzoliCorrado De VitoMaddalena D'AddarioPaolo VillariRandomized evidence for vaccine immunogenicity and safety is urgently needed in the setting of pandemics with new emerging infectious agents. We carried out an observational survey to evaluate how many randomized controlled trials testing 2009 H1N1 vaccines were published among those registered, and what was the time lag from their start to publication and from their completion to publication.PubMed, EMBASE and 9 clinical trial registries were searched for eligible randomized controlled trials. The units of the analysis were single randomized trials on any individual receiving influenza vaccines in any setting.73 eligible trials were identified that had been registered in 2009-2010. By June 30, 2011 only 21 (29%) of these trials had been published, representing 38% of the randomized sample size (19905 of 52765). Trials starting later were published less rapidly (hazard ratio 0.42 per month; 95% Confidence Interval: 0.27 to 0.64; p<0.001). Similarly, trials completed later were published less rapidly (hazard ratio 0.43 per month; 95% CI: 0.27 to 0.67; p<0.001). Randomized controlled trials were completed promptly (median, 5 months from start to completion), but only a minority were subsequently published.Most registered randomized trials on vaccines for the H1N1 pandemic are not published in the peer-reviewed literature.http://europepmc.org/articles/PMC3229554?pdf=render
collection DOAJ
language English
format Article
sources DOAJ
author John P A Ioannidis
Lamberto Manzoli
Corrado De Vito
Maddalena D'Addario
Paolo Villari
spellingShingle John P A Ioannidis
Lamberto Manzoli
Corrado De Vito
Maddalena D'Addario
Paolo Villari
Publication delay of randomized trials on 2009 influenza A (H1N1) vaccination.
PLoS ONE
author_facet John P A Ioannidis
Lamberto Manzoli
Corrado De Vito
Maddalena D'Addario
Paolo Villari
author_sort John P A Ioannidis
title Publication delay of randomized trials on 2009 influenza A (H1N1) vaccination.
title_short Publication delay of randomized trials on 2009 influenza A (H1N1) vaccination.
title_full Publication delay of randomized trials on 2009 influenza A (H1N1) vaccination.
title_fullStr Publication delay of randomized trials on 2009 influenza A (H1N1) vaccination.
title_full_unstemmed Publication delay of randomized trials on 2009 influenza A (H1N1) vaccination.
title_sort publication delay of randomized trials on 2009 influenza a (h1n1) vaccination.
publisher Public Library of Science (PLoS)
series PLoS ONE
issn 1932-6203
publishDate 2011-01-01
description Randomized evidence for vaccine immunogenicity and safety is urgently needed in the setting of pandemics with new emerging infectious agents. We carried out an observational survey to evaluate how many randomized controlled trials testing 2009 H1N1 vaccines were published among those registered, and what was the time lag from their start to publication and from their completion to publication.PubMed, EMBASE and 9 clinical trial registries were searched for eligible randomized controlled trials. The units of the analysis were single randomized trials on any individual receiving influenza vaccines in any setting.73 eligible trials were identified that had been registered in 2009-2010. By June 30, 2011 only 21 (29%) of these trials had been published, representing 38% of the randomized sample size (19905 of 52765). Trials starting later were published less rapidly (hazard ratio 0.42 per month; 95% Confidence Interval: 0.27 to 0.64; p<0.001). Similarly, trials completed later were published less rapidly (hazard ratio 0.43 per month; 95% CI: 0.27 to 0.67; p<0.001). Randomized controlled trials were completed promptly (median, 5 months from start to completion), but only a minority were subsequently published.Most registered randomized trials on vaccines for the H1N1 pandemic are not published in the peer-reviewed literature.
url http://europepmc.org/articles/PMC3229554?pdf=render
work_keys_str_mv AT johnpaioannidis publicationdelayofrandomizedtrialson2009influenzaah1n1vaccination
AT lambertomanzoli publicationdelayofrandomizedtrialson2009influenzaah1n1vaccination
AT corradodevito publicationdelayofrandomizedtrialson2009influenzaah1n1vaccination
AT maddalenadaddario publicationdelayofrandomizedtrialson2009influenzaah1n1vaccination
AT paolovillari publicationdelayofrandomizedtrialson2009influenzaah1n1vaccination
_version_ 1725275144146911232